New partnership uses data to help drug developers with patient recruitment

Cerba Research, a healthcare diagnostic company, has formed a partnership with Biokortex, provider of digital solutions to the healthcare sector. This partnership will leverage patient biological and medical data to support drug developers and CROs with patient identification and recruitment activity.

“Cerba Healthcare and Cerba Research are committed to investing in technologies that will reduce the patient burden of participating in clinical trials and help our clients to accelerate their development strategy. Biokortex will allow them to prospectively identify potential patients and offer them a safer alternative to access innovative treatments,” said Mario Papillon, CEO at Cerba Research.

“Digitisation is providing an impetus to move away from centralised, high-cost, and difficult-to-access settings to more virtual, patient-centric, and efficient clinical trials models. Cerba Healthcare is the perfect partner to build the future patient’s care path,” said Biokortex CEO Adrien Ko.

The benefits of this new partnership are said to include:

  • Leveraging patients’ biological and medical data — as well as biomarker and genetic data from the Cerba Healthcare network — which comprises over 25 million patients per year from over 1,000 sites located in Europe, Africa, and North America
  • A global footprint with data on global testing, frequency, and accuracy
  • A platform for screening and companion diagnostic testing across Europe and Africa
  • By connecting real-world laboratory data from clinical sites and digitising patient data, this partnership will optimise patient recruitment for precision medicine by identifying patients expected to respond to your product — moving efficiently into clinical trials and allowing patients to receive information on new therapies at the right time

Image credit: H Heyerlein

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free